phytohemagglutinin L4

04/01/2000 - "Preliminary reports on other tumors treated with PWM indicate some impressive responses have occurred, although they also suggest that Mann's regimen may sometimes require adjustments in dosages and other variables previously reviewed in theoretical PHA-L4 models, to which this case report now contributes validity."
08/15/1987 - "Considerably higher (greater than 10) concentrations of PHA isolectin with four E subunits were needed to induce similar growth inhibition of the tumor cells, as compared to PHA-L4. "
04/01/1998 - "For cancer therapy, this represents a highly effective deviation from the stimulation of multiple pathways of immune response usually surmised with mitogens such as PHA-L4. "
12/01/2003 - "Following is a resumé of the critical attributes of mitogen therapy relative to the management of malignant tumors: (1) An inherent capability to recognize and destroy mutated or damaged tissues without altering those that are normal; (2) The capacity to induce global immunostimulation by the nonspecific activation of CD4+/- and CD8+/- cells with balanced production of a variety of cytokines able to stimulate B cell, NK cell, and macrophage pathways, at the same time augmenting myeloproliferation; (3) The ability to afford protection and accelerated recovery from the immunosuppressive and myelosuppressive effects of tumors, infections, GvH reactions, and autoimmune states along with the surgery, irradiation, chemotherapeutic agents, antibiotics, and suppressive factors used in their management; (4) Berke's in vitro data from the lectin-dependent cellular cytotoxicity (LDCC) system showing that systemic administration of mitogens such as PHA-L4 should indeed prove destructive to virtually any type of malignancy, leaving normal tissues undamaged; and (5) The potential of these activities to reconstitute the immune competence so vital to lasting cures. "
06/01/1990 - "Evidence is presented that suggests that PHA-L4 may exert the therapeutic effects of a theoretical ideal biological response modifier through its ability to do the following: to assist remission induction in certain malignancies, to exhibit direct antitumor cytotoxic effects, to enhance antineoplastic effect of radiation and chemotherapy, to decrease the liability to malignant transformation, to promote differentiation and restore normal growth responses in neoplastic cells, to manifest minimal liability to suppressor activity that would inhibit tumor rejection or antitumor cytotoxicity, to repress graft rejection and graft-versus-host responses and amplify the immunosuppressive effects of other agents in allograft transplantations, to display a direct protective effect against damage from radiation and chemotherapy, to stimulate normal myelopoiesis, to reinforce responses against various infections, to amplify tumor immunogenicity, and to attract mononuclear cells to sites of injection or local application."

06/01/1997 - "The proper sequence of this treatment should be maximum reduction of the HIV-1 load with drug combinations, control of complicating infection by other means to reduce mitogen-induced tissue necrosis, and addition of systemic PHA-L4 administration regulated to maintain a 5-10 micrograms/mL serum concentration. "
12/01/2003 - "Following is a resumé of the critical attributes of mitogen therapy relative to the management of malignant tumors: (1) An inherent capability to recognize and destroy mutated or damaged tissues without altering those that are normal; (2) The capacity to induce global immunostimulation by the nonspecific activation of CD4+/- and CD8+/- cells with balanced production of a variety of cytokines able to stimulate B cell, NK cell, and macrophage pathways, at the same time augmenting myeloproliferation; (3) The ability to afford protection and accelerated recovery from the immunosuppressive and myelosuppressive effects of tumors, infections, GvH reactions, and autoimmune states along with the surgery, irradiation, chemotherapeutic agents, antibiotics, and suppressive factors used in their management; (4) Berke's in vitro data from the lectin-dependent cellular cytotoxicity (LDCC) system showing that systemic administration of mitogens such as PHA-L4 should indeed prove destructive to virtually any type of malignancy, leaving normal tissues undamaged; and (5) The potential of these activities to reconstitute the immune competence so vital to lasting cures. "
06/01/1990 - "Evidence is presented that suggests that PHA-L4 may exert the therapeutic effects of a theoretical ideal biological response modifier through its ability to do the following: to assist remission induction in certain malignancies, to exhibit direct antitumor cytotoxic effects, to enhance antineoplastic effect of radiation and chemotherapy, to decrease the liability to malignant transformation, to promote differentiation and restore normal growth responses in neoplastic cells, to manifest minimal liability to suppressor activity that would inhibit tumor rejection or antitumor cytotoxicity, to repress graft rejection and graft-versus-host responses and amplify the immunosuppressive effects of other agents in allograft transplantations, to display a direct protective effect against damage from radiation and chemotherapy, to stimulate normal myelopoiesis, to reinforce responses against various infections, to amplify tumor immunogenicity, and to attract mononuclear cells to sites of injection or local application."

12/01/1987 - "Phytohemagglutinin and its isolectins PHA-E4 an PHA-L4 act antiproliferatively on an actively dividing leukemia T-cell line. "

06/01/1997 - "The proper sequence of this treatment should be maximum reduction of the HIV-1 load with drug combinations, control of complicating infection by other means to reduce mitogen-induced tissue necrosis, and addition of systemic PHA-L4 administration regulated to maintain a 5-10 micrograms/mL serum concentration. "